Physician profile
Lamisa S Rayside
NPI 1205151677
$6,672.19
in general payments reported to CMS, 2019-2025
39 companies · $860 in 2025
The $860 reported for 2025 was more than what 85% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,382 · 2022: $2,183 · 2023: $1,118 · 2024: $1,130 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,964 · Travel and Lodging: $108 · Education: $36.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,963.58 |
| Travel and Lodging | $107.57 |
| Education | $36.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,398.53 | 2021-2025 | Intracept, Wavewriter Alpha Prime 16, General - Therapies |
| Abbvie INC. | $747.60 | 2021-2025 | |
| Nevro Corp. | $399.38 | 2021-2024 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $396.86 | 2021-2024 | Relistor |
| Gilead Sciences, INC. | $308.04 | 2021-2024 | Epclusa |
| Biogen, INC. | $301.72 | 2022-2024 | |
| Scilex Pharmaceuticals INC. | $287.73 | 2021-2024 | Ztlido |
| Neurocrine Biosciences, INC. | $248.54 | 2023-2025 | Ingrezza |
| Paratek Pharmaceuticals, INC. | $226.49 | 2022-2023 | Nuzyra |
| Novo Nordisk INC | $220.71 | 2024-2025 | |
| Genentech USA, INC. | $215.53 | 2021-2023 | Evrysdi |
| Medtronic, INC. | $182.07 | 2024 | Synchromedii |
| Grt US Holding, INC. | $161.50 | 2021 | |
| Stimwave Technologies Incorporated | $126.88 | 2021 | |
| Grifols USA, LLC | $126.63 | 2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lamisa Rayside listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.